In toto, our study shows that SHIP1 activity in PBMCs is decreased in adult CD patients either through reduced intrinsic enxymatic activity or reduced protein expression, and we propose that in addition to ATG16L1, SHIP1 may contribute to the risk conferred by the 2q37 CD risk locus. Here, ATG16L1 is linked to Cowden disease.